HOUSTON--(BUSINESS WIRE)--Dec. 23, 2014--
Bellicum Pharmaceuticals, Inc. (Nasdaq:BLCM), a biopharmaceutical
company focused on discovering and developing novel cellular
immunotherapies, today announced the closing of its underwritten initial
public offering of common stock, including the underwriters’ exercise of
their option to purchase an additional 1,102,500 shares at the public
offering price of $19.00 per share. The underwriters’ option brought the
total number of shares of common stock sold by Bellicum to 8,452,500
shares and increased the amount of gross proceeds raised in the offering
to approximately $160.6 million, prior to deducting the underwriting
discount and estimated expenses of the offering.
Jefferies LLC, Citigroup Global Markets Inc. and Piper Jaffray & Co.
acted as joint book running managers for the offering and Trout Capital
LLC acted as co-manager for the offering.
The shares were offered by Bellicum pursuant to a registration statement
that was declared effective by the Securities and Exchange Commission
("SEC") on December 17, 2014. A prospectus relating to and describing
the terms of the offering has been filed with the SEC and is available
on the SEC's web site at www.sec.gov.
Copies of the prospectus relating to this offering can be obtained from
Jefferies LLC, Attention: Equity Syndicate Prospectus Department, 520
Madison Avenue, 2nd Floor, New York, NY 10022, by telephone at (877)
547-6340, or by e-mail at Prospectus_Department@Jefferies.com;
Citigroup Global Markets Inc., c/o Broadridge Financial Solutions, 1155
Long Island Avenue, Edgewood, NY 11717, by email at prospectus@citi.com,
or by telephone at 1-800-831-9146; or Piper Jaffray & Co., Attention:
Equity Capital Markets, 800 Nicollet Mall, J12S03, Minneapolis, MN
55402, or by telephone at 800-747-3924 or by e-mail at prospectus@pjc.com.
This press release shall not constitute an offer to sell or the
solicitation of an offer to buy, nor shall there be any sale of these
securities in any state or other jurisdiction in which such an offer,
solicitation or sale would be unlawful prior to registration or
qualification under the securities laws of any such state or other
jurisdiction.
About Bellicum Pharmaceuticals
Bellicum is a clinical stage biopharmaceutical company focused on
discovering and developing novel cellular immunotherapies for various
forms of cancer, including hematological cancers and solid tumors, as
well as orphan inherited blood disorders. The Company is using its
proprietary Chemical Induction of Dimerization, or CID, technology
platform to engineer and control components of the immune system in real
time. The Company is developing next-generation product candidates in
some of the most important areas of cellular immunotherapy, including
hematopoietic stem cell transplantation, or HSCT, CAR T cell therapy,
and dendritic cell vaccines.
Source: Bellicum Pharmaceuticals
Source: Bellicum Pharmaceuticals, Inc.
Investors:
Bellicum Pharmaceuticals
Alan Musso, 832-384-1116
Chief
Financial Officer
amusso@bellicum.com
or
Media:
Brad
Miles, 646-513-3125
bmiles@bmccommunications.com
